| Abstrakt: |
Objectives. To evaluate the efficacy and safety of combination therapy for patients with post-COVID asthenia syndrome (AS) using the multicomponent bioregulatory medicines Traumeel S, Ubichinon Compositum, and Coenzyme Compositum. Materials and methods. The study included 104 patients (median age 39 [30; 48] years) who had had COVID-19 and achieved clinical recovery from the acute infectious process and experienced AS for periods from two weeks to six months with an asthenia visual analog scale (VAS) score of at least 30 points. Before the start of the study, physical examination was conducted and patients' conditions were assessed using questionnaires and scales: an asthenia VAS, a subjective asthenia rating scale (the Multidimensional Fatigue Inventory MFI-20), the L. D. Malkova Asthenia Syndrome Scale, the EQ-5D quality of life questionnaire, and the A. M. Vein Signs of Autonomic Disorders Questionnaire. Patients in the treatment group received Traumeel S, 1 tablet 3 times a day, along with Ubichinon Compositum and Coenzyme Compositum, 2.2 ml, intramuscularly, alternating every other day, for one month (15 injections of each drug per course of treatment). Patients in the reference group received 100 mg Eleutherococcus extract for 30 days, 2 tablets 2 times a day before meals, along with a combined B group vitamins formulation. Patients' status was monitored at follow-up visits at two weeks and one month from the start of treatment and one month after treatment was completed. Results. Patients in the treatment group showed a positive effect. Patients in the reference group displayed no correlation between the quality of life and physical and mental asthenia, while the treatment group showed an inverse correlation with the severity of AS, such that improved quality of life was associated with decreased severity of AS. Significant reductions in headache and musculoskeletal pain were demonstrated in the treatment group. Conclusions. Combination therapy in patients with post-COVID AS using Traumeel S, Ubichinon Compositum, and Coenzyme Compositum produced better outcomes as compared with the reference group. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink